Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07137481) titled 'Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies' on Aug. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Hematological Malignancies
Intervention:
Drug: C9/CD5CAR/IL-15 NK cells
Drug: Rituximab
Drug: Fludarabine
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: Februa...